Illumina Inc. cut its full-year adjusted profit guidance for the second time in three months as it grapples with the impact of tariffs and China banning imports of its gene-sequencing machines.
The maker of DNA sequencing machines now expects adjusted earnings of $4.20 per share to $4.30 per share for the fiscal year, it said in a statement. That’s a reduction from its March forecast of $4.50 a share, which was down from the $4.50 per share to $4.65 a share it offered in February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.